P&G Q4 update
This article was originally published in The Rose Sheet
Executive Summary
Procter & Gamble predicts higher than expected earnings growth for the fourth quarter ending June 30, based on strong sales volume. Core earnings, excluding restructuring charges, to be up in the high teens and volume growth forecast at 9%-10%, led by the Clairol acquisition and "strong performances by the beauty care, health care and fabric and home care business units, especially in North America," firm says. Sales, excluding foreign exchange, predicted to rise in the mid- to high-single-digit percent range. P&G will report fourth quarter and year-end results Aug. 5...
You may also be interested in...
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.